Credit Suisse analyst Soyun Shin upgrades Coupang (NYSE:CPNG) from Neutral to Outperform and lowers the price target from $28 to $19.
IN8bio Announces Preclinical Data For Gamma-Delta CAR Platform And Launches New CD33 Program At AACR Annual Meeting 2023
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen.
CAR platform